Novel immunosuppressants, SNF4435C and D produced by a strain of Streptomyces spectabilis, were examined for their pharmacodynamical profiles. SNF4435C and D suppressed the responses of both murine splenocytes and human peripheral blood lymphocytes in the mouse MLR experiments, SNF4435C and D did not block the production of interleukin-2 (IL-2) and the compounds-induced suppression was not restored by the addition of exogeneous IL-2. In addition, the significant inhibitory action was still retained even when SNF4435C or D was added after 48 hours from the start of the culture. These results were distinct from the behaviors observed with FK-506. SNF4435C, the major component, suppressed mouse delayed type hypersensitivity (DTH) and prolonged rat skin allograft survival.
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In the course of screening for bioactive compounds derived from microbial products, we found novel immunosuppressants, SNF4435C and D, in the culture broth of a strain of Streptomyces spectabilis1,2). The compounds are nitrophenyl pyrones having an intriguing tricyclic ring system and are diastereoisomers of each other. 
Materials and Methods
Reagents SNF4435C and D were isolated from the culture broth of a strain of Streptomyces spectabilis SNF4435 in our laboratory, as described previously1). The structures of these compounds are illustrated in Fig. 1 inhibition) were determined from the dose-response curve.
The mean of the counts of triplicate measurement for each sample was determined.
Human MLR Human MLR was carried out using the methodology (male, 7 weeks old) were transplanted to the dorsum of recipient rats, F344 (male, 7 weeks old) and covered with sterile bactericidal gauze. The affected part was then wrapped with an elastic bandage. After 3 days from the transplantation, the dressings were removed. Each graft was inspected daily until rejection, which was defined as more than 90% necrosis of the graft epithelium. The test compound suspended in 0.9% NaCl solution containing 20% HCO-60 (Nikko chemicals) was injected subcutaneously (s.c.) into the rats once a day for the 10 consecutive days, from the day of transplantation.
Statistical Analysis
The results of the DTH assay were evaluated by the Dunnett two-tailed test, and skin graft survival times were compared by the Mann-Whitney U test. P values less than 0.05 were considered to be significant.
Results
In Vitro Immunosuppressive Activity
The effects of SNF4435C and D on mouse and human mixed lymphocyte reactions (MLR) were examined in to the culture after 0, 24 or 48 hours from the start of the culture, and the percent inhibition was compared in the MLR (Fig. 3) . The potent inhibitory activities of SNF4435C and D were still observed even when these compounds were added after 48 hours. By contrast, FK-506 exhibited little inhibitory activity when added after 48 hours (percent inhibition by the addition of the compounds at 0, 24 and 48 hours later: SNF4435C, 90%, 65%, 42%; SNF4435D, 95%, 68%, 48%; FK-506, 87%, 20%, 7%).
In Vivo Immunosuppressive Activity
To elucidate the potency and efficacy of SNF4435C, the transplantation. In this model, the rejection process became visible from day 6 to 7 after transplantation and immediately culminated into complete graft necrosis. As shown in Table 2 , the median survival time of skin grafts was 8.0 days in the vehicle-treated group. SNF4435C at a dose of 3mg/kg did not prolong the graft rejection. A significant prolongation of skin graft survival was observed at doses of more than 10mg/kg in a dose-dependent manner. SNF4435C at a dose of 30mg/kg prolonged median allograft survival time to 16 days. At this dose, no severe loss of body weight was observed. On the other hand, a significant prolongation of skin graft survival was obtained at a dose of 0.3 or 1mg/kg in the FK-506-treated groups.
Discussion
In this report, we demonstrate the pharmacodynamaical profiles of SNF4435C and D, immunosuppressants produced by a strain of Streptomyces spectabilis. SNF4435C, the major component, was effective in suppressing the immune responses in both mouse delayed type hypersensitivity (DTH) reaction and rat allogeneic skin graft rejection. SNF4435C suppressed the DTH responses in all tested administration routes. But the efficacy of SNF4435C by oral administration was inferior to that by intraperitoneal or subcutaneous administration at the same dose (10mg/kg), suggesting poor bioavailability of the orally administered compound. In the skin graft model, subcutaneous administration of 10-30mg/kg SNF4435C was effective for prolongation of the survival. FK-506 was 50 to 100 times more potent than SNF4435C in prolongation of rat skin allograft survival. An acute toxicity test revealed that the LD50 of subcutaneously administered SNF4435C in mice and rats was more than 100mg/kg, which is over 10-fold higher than the effective doses in in vivo immunosuppression. It is likely that SNF4435C is less toxic than FK-506, although detailed comparative studies with FK-506 are necessary.
Immunosuppressants are used not only to prevent rejection against the transplanted organs or tissues, but also to remedy autoimmune or allergic diseases. However, strategies for the chemotherapy of the diseases have not been established yet. The absolute potency of SNF4435C may be inferior to that of FK-506, when assessed by the skin graft model. However, SNF4435C and D have different immunosuppressive mechanisms from FK-506 and CsA, and preferentially suppress the mitogen-induced B-cell proliferation compared with T-cell proliferation1). From the point of view of these possible mechanisms, SNF4435C and D might become more effective means for immunosuppressive therapy. The results in this paper will countenance further preclinical evaluation of the compounds as candidates for immunosuppressive agents.
